17 . 12 .2025
Press release
New published data confirms Nemluvio® (nemolizumab) can rapidly relieve itch and improve sleep in as early as two days in both atopic dermatitis and prurigo nodularis
11 . 12 .2025
News story
GAIN ASCENT Summit, our training program for emerging injectors, marks the end of GAIN's first decade
11 . 12 .2025
Press release
Galderma announces first patient enrollment in study to assess nemolizumab in adults with Chronic Pruritus of Unknown Origin
05 . 12 .2025
Press release
Galderma opens up new chapter for Sculptra® with MDR certification and new expanded indication for body
04 . 12 .2025
Press release
Galderma secures ‘BBB’ credit rating with positive outlook from S&P Global Ratings
17 . 11 .2025
Press release
ASDS 2025: Compelling new data on Restylane, Sculptra and Relfydess highlight Galderma’s innovative Injectable Aesthetics portfolio and pipeline
